Boston, MA 10/06/2014 (wallstreetpr) – According to reports, Ebola; the deadliest virus of the present has entered in America. Recently two new cases of Ebola were found in Texas. As soon as the news was confirmed, various drug manufacturing companies started coming out with their Ebola Vaccines at earliest. Among all these companies, GlaxoSmithKline plc (ADR) (NYSE:GSK) has also announced the production of experimental Ebola vaccine. As per the information, it will be producing 10,000 experimental vaccines at first.
Insights of the matter:
Ebola caused thousands of deaths and infections in Africa over the past one year or so. No drug company could come up with a permanent solution of this problem. Even though developed countries like US, UK and others helped Africa in overcoming from this problem, but things didn’t improve. If today’s condition is taken into consideration, Ebola-infected people are doubling every week in Africa. Recently two people in Texas were found infected with this deathly virus, which increased problems for America significantly. Only one positive of this outburst that world has seen as of now is nothing but eye-steering growth in the shares of those top pharmaceutical companies that have developed experimental drugs for Ebola.
According to a survey, almost 12 million American people are suffering from various infections like Chagas disease, West Nile virus or dengue fever. With the entrance of Ebola in America, the problems of the Obama Government have increased tremendously. So far Ebola has infected more than 6,500 people mainly in African countries like Guinea, Sierra Leone and Liberia. World Health Organization has already warned all the countries that if not stopped, Ebola will infect at approximately 20,000 people by November. GlaxoSmithKline plc (ADR) (NYSE:GSK) has come up with an experimental drug for Ebola and if clinical trials go well, then it will start supplying the drug to WHO by the starting of 2015.